Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.15 USD | -4.24% | -0.54% | +48.36% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.36% | 2.38B | |
+75.69% | 12.57B | |
-21.92% | 7.61B | |
+6.48% | 6.63B | |
+15.67% | 5.53B | |
-15.36% | 4.89B | |
+16.83% | 4.17B | |
-21.75% | 3.99B | |
-23.78% | 2.88B | |
+1.86% | 2.08B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients